252 related articles for article (PubMed ID: 34911649)
1. Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial.
Cochetti G; Rossi de Vermandois JA; Maulà V; Cari L; Cagnani R; Suvieri C; Balducci PM; Paladini A; Del Zingaro M; Nocentini G; Mearini E
Urol Oncol; 2022 Mar; 40(3):105.e11-105.e18. PubMed ID: 34911649
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
[TBL] [Abstract][Full Text] [Related]
3. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
4. Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies.
Hermann GG; Mogensen K; Toft BG; Glenthøj A; Pedersen HM
Scand J Urol Nephrol; 2012 Feb; 46(1):31-6. PubMed ID: 22150596
[TBL] [Abstract][Full Text] [Related]
5. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
[TBL] [Abstract][Full Text] [Related]
6. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.
Pierconti F; Martini M; Cenci T; Fiorentino V; Gianfrancesco LD; Ragonese M; Bientinesi R; Rossi E; Larocca LM; Racioppi M; Bassi PF
Urol Oncol; 2022 Mar; 40(3):108.e19-108.e25. PubMed ID: 34903453
[TBL] [Abstract][Full Text] [Related]
7. The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer.
Ragonese M; Gianfrancesco LD; Palermo G; Pierconti F; Martini M; Foti M; Bassi P; Racioppi M
Clin Genitourin Cancer; 2022 Aug; 20(4):e271-e275. PubMed ID: 35871875
[TBL] [Abstract][Full Text] [Related]
8. Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
Fiorentino V; Pizzimenti C; Franchina M; Rossi ED; Tralongo P; Carlino A; Larocca LM; Martini M; Fadda G; Pierconti F
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569864
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of photodynamic diagnosis for challenging TUR- Bt cases including muscle invasive bladder cancer, BCG failure or 2nd-TUR.
Takai T; Inamoto T; Komura K; Yoshikawa Y; Uchimoto T; Saito K; Tanda N; Kouno J; Minami K; Uehara H; Takahara K; Hirano H; Nomi H; Kiyama S; Azuma H
Asian Pac J Cancer Prev; 2015; 16(6):2297-301. PubMed ID: 25824753
[TBL] [Abstract][Full Text] [Related]
11. Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer.
Ray ER; Chatterton K; Thomas K; Khan MS; Chandra A; O'Brien TS
J Endourol; 2009 Jun; 23(6):983-8. PubMed ID: 19441882
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.
Mowatt G; Zhu S; Kilonzo M; Boachie C; Fraser C; Griffiths TR; N'Dow J; Nabi G; Cook J; Vale L
Health Technol Assess; 2010 Jan; 14(4):1-331, iii-iv. PubMed ID: 20082749
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
14. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
Pycha S; Trenti E; Mian C; Schwienbacher C; Hanspeter E; Palermo M; Pycha A; Danuser H; D'Elia C
World J Urol; 2023 May; 41(5):1323-1328. PubMed ID: 36929411
[TBL] [Abstract][Full Text] [Related]
16. Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis.
Drăgoescu PO; Tudorache Ş; Drocaş AI; Mitroi G; Pănuş A; Drăgoescu NAM; Meşină C; Mititelu CD; Stănculescu AD; Mohamed G; Tomescu PI
Rom J Morphol Embryol; 2017; 58(4):1279-1283. PubMed ID: 29556618
[TBL] [Abstract][Full Text] [Related]
17. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
[TBL] [Abstract][Full Text] [Related]
18. The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA).
Inoue K; Matsuyama H; Fujimoto K; Hirao Y; Watanabe H; Ozono S; Oyama M; Ueno M; Sugimura Y; Shiina H; Mimata H; Azuma H; Nagase Y; Matsubara A; Ito YM; Shuin T
Photodiagnosis Photodyn Ther; 2016 Mar; 13():91-96. PubMed ID: 26751700
[TBL] [Abstract][Full Text] [Related]
19. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
20. Early Photodynamic Diagnosis Cystoscopy After Bacillus Calmette-Guérin (BCG) Induction for High-Risk Nonmuscle Invasive Bladder Cancer Significantly Increased the Detection of BCG Refractory Tumors.
Morelli M; Baboudjian M; Vanacore D; Gondran-Tellier B; McManus R; Karsenty G; Lechevallier E; Montanari E; Boissier R
J Endourol; 2021 Dec; 35(12):1824-1828. PubMed ID: 34107773
[No Abstract] [Full Text] [Related]
[Next] [New Search]
